Blocked and tackled by the FDA, AcelRx spikes on upbeat update on PhIII pain study

After subjecting investors to an embarrassing about-face when it was forced to concede a major setback at the FDA last year, AcelRx managed to garner a spike in its share price ($ACRX) this morning with its positive assessment of interim data from another one of its Phase III pain therapy studies.

The Redwood City, CA-based biotech reports that the 40 patients dosed so far with ARX-04 in the Phase III trial demonstrated a quick, sharp drop in pain scores after turning up at the ER. ARX-04 uses a prefilled applicator to deliver 30-mcg sufentanil tablets sublingually, which is intended to provide fast relief after an injury.

AcelRx achieved a 14% spike in its share price on the news, but the stock is still trading far below its 12-month high. Last spring the biotech was forced to reverse itself and concede that the FDA was indeed requiring a new study of Zalviso before it would reconsider an approval. Company execs had assured investors the year before that the FDA's objections could be dealt with easily, and suffered a sharp erosion of confidence that wasn't helped when the FDA refused to even discuss the matter.

The company announced last month that it is launching another Phase III for Zalviso--its fourth--which will recruit 310 patients.

The biotech reported last fall that ARX-04 had met primary and secondary endpoints in a separate Phase III study last year.

"In addition to its analgesic efficacy, we assessed the cognitive impact of ARX‑04 on patients in this study," noted company co-founder Dr. Pamela Palmer. "We conducted this analysis at the request of the United States Department of Defense, since drug-induced cognitive impairment on the battlefield is a particular concern. Using a well-known cognitive test, the Six-Item Screener, patients demonstrated no change in mean test scores before and after dosing."

- here's the release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.